Rochester, N.Y. -- Eastman Kodak Company has signed an agreement with Novadaq Technologies Inc. (Toronto, Canada) to be the sole European and Emerging Markets distributor of Novadaq's SPY© Intra-operative Imaging System which is used during cardiac surgery.

Under the agreement, Kodak will sell Novadaq's SPY System directly and through dealers to healthcare providers across Europe and Emerging Markets.

Novadaq's SPY System is a fluorescent imaging system that enables cardiac surgeons to assess coronary vasculature, and to identify and revise anatomic and technical deficiencies while the patient is still in the operating room.

In 2005, Kodak was selected as the sole U.S. service provider for the SPY System, based on its expertise in medical imaging and geographic coverage offered by its extensive Services organization. Kodak currently is servicing an installed base of SPY Systems in over 50 leading healthcare facilities in the U.S.

"Kodak has strong relationships with physicians and hospitals throughout the world and an experienced and knowledgeable sales force that healthcare providers trust," said Gordon Moore, Product Line Manager, MVES Surgical Imaging. "Together our companies will strive to accelerate the acceptance of the SPY System to make it the standard of care during cardiac surgery."

"Cardiac surgeons have seen the significant benefits the SPY System provides during cardiac surgery, including coronary artery bypass graft surgery which is one of the most challenging surgeries performed, " said Arun Menawat, CEO and President of Novadaq Technologies. "With Kodak's worldwide presence in the medical imaging market, we expect to see a successful rollout of the SPY System in Europe and Emerging Markets just as we have in the U.S."

About Novadaq Technologies

Novadaq Technologies Inc. (TSX: NDQ) develops and commercializes medical devices based on its proprietary imaging platform for the diagnosis and treatment of human vascular and ophthalmic diseases and conditions. Novadaq's SPY© Intra-operative Imaging System, commercially available worldwide, enables cardiac surgeons to visually assess coronary vasculature and bypass graft functionality during the course of open-heart surgery. Novadaq's ophthalmic product, the OPTTX© System, is aimed at the diagnosis, evaluation and treatment of wet Age-related Macular Degeneration (AMD) by using the same core imaging technology that is used in the SPY System. The OPTTX System filed for CE Mark at the end of Q2 2006 and expects a limited launch in Europe by year end. Novadaq's product for urology, LUNATM is designed to enable surgeons to visualize nerve bundles during the course of urological procedures such as radical prostatectomy in order to reduce negative outcomes including impotency. For more information, please visit the company's website at www.novadaq.com.

More Industry Headlines